TrialOrphanet journal of rare diseases2025

Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome.

Whitney Eng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.